|Dr. Severin Schwan||CEO & Exec. Director||8,03M||N/A||1967|
|Dr. Alan Hippe||Chief Financial & IT Officer||4,02M||N/A||1967|
|Dr. Karl Mahler||Head of Investor Relations||N/A||N/A||N/A|
|Dr. Urs Jaisli||Chief Compliance Officer||N/A||N/A||1956|
|Ms. Claudia BÃ¶ckstiegel||Gen. Counsel||N/A||N/A||1964|
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Further, the company discovers, develops, and delivers gene therapies. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
O QualityScore de governança da ISS da Roche Holding AG a partir de 8 de dezembro de 2019 é 5. As principais pontuações para Auditoria são: 1; Conselho: 3; Direitos de Acionistas: 1; Compensação: 8.